about
Insights into the pharmacokinetic properties of antitubercular drugs.Dried blood spots: concepts, present status, and future perspectives in bioanalysis.Novel pre-clinical methodologies for pharmacokinetic drug-drug interaction studies: spotlight on "humanized" animal models.Model based population PK-PD analysis of furosemide for BP lowering effect: A comparative study in primary and secondary hypertension.A combination of complexation and self-nanoemulsifying drug delivery system for enhancing oral bioavailability and anticancer efficacy of curcumin.Identification of a diverse indole-2-carboxamides as a potent antileishmanial chemotypes.Preclinical pharmacokinetics and ADME characterization of a novel anticancer chalcone, cardamonin.Identification of gallic acid based glycoconjugates as a novel tubulin polymerization inhibitors.Simultaneous LC-MS-MS Determination of Lopinavir and Rifabutin in Human Plasma.Identification of β-Amino alcohol grafted 1,4,5 trisubstituted 1,2,3-triazoles as potent antimalarial agents.Synthesis and bioevaluation of novel 4-aminoquinoline-tetrazole derivatives as potent antimalarial agents.Identification of novel phenyl butenonyl C-glycosides with ureidyl and sulfonamidyl moieties as antimalarial agents.Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine.Role of enterohepatic recirculation in drug disposition: cooperation and complications.Ameliorative potential of ferulic acid in vincristine-induced painful neuropathy in rats: An evidence of behavioral and biochemical examination.Effect of arteether and pyrimethamine coadministration on the pharmacokinetic and pharmacodynamic profile of ormeloxifene.Quantification of highly selective sigma-1 receptor antagonist CM304 using liquid chromatography tandem mass spectrometry and its application to a pre-clinical pharmacokinetic study.Coadministration of HMG-CoA reductase inhibitors, atorvastatin and rosuvastatin, does not affect contraceptive efficacy of centchroman.Gender-related pharmacokinetics and bioavailability of a novel anticancer chalcone, cardamonin, in rats determined by liquid chromatography tandem mass spectrometry.LC-coupled ESI MS for quantification of miltefosine in human and hamster plasma.Doxorubicin Hydrochloride Loaded Zymosan-Polyethylenimine Biopolymeric Nanoparticles for Dual 'Chemoimmunotherapeutic' Intervention in Breast Cancer.Preclinical Evaluation of DMA, a Bisbenzimidazole, as Radioprotector: Toxicity, Pharmacokinetics, and Biodistribution Studies in Balb/c Mice.Rapid quantitative analysis of ormeloxifene and its active metabolite, 7-desmethyl ormeloxifene, in rat plasma using liquid chromatography-tandem mass spectrometry.A stable isotope dilution tandem mass spectrometry method of major kavalactones and its applications.Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom)A novel proteotoxic combination therapy for EGFR+ and HER2+ cancersA selective BCL-XL PROTAC degrader achieves safe and potent antitumor activitySimultaneous quantification of ten key Kratom alkaloids in Mitragyna speciosa leaf extracts and commercial products by ultra-performance liquid chromatography-tandem mass spectrometry
P50
Q30251497-672DE5C6-AE8D-4117-A15B-B64F2BAF719CQ38201371-E490D08A-8A46-474A-9567-6695FBE1C00AQ38255685-AFAD3FCC-C89F-4FDD-A515-6652A43EE9BBQ38618133-560EB6A9-516B-498E-A785-C2FF3D47A395Q38744748-B4155E0A-524F-4C3B-99F8-2AD7F27B047DQ38796997-4A009E3D-3766-4EF8-95D1-470AB212CA1BQ38802864-11056205-9EF2-4655-9C9B-54B6227077EDQ40219453-36B20AD0-2339-4E62-B4FA-B019D0D48090Q40277577-C372A9F8-7858-44DA-ACE0-DEA1493B2532Q41915949-CF163649-DA07-4EF3-828E-423009F70508Q41925265-60AC6130-5F1A-46A3-9687-EC2809CB553BQ42808168-C35D0338-15AC-481F-BE0D-D29E9282F85AQ45759119-EE6BAD2E-9D6C-4F8D-8596-303439354482Q46578287-684EA215-282E-40A7-9DDE-64691F75A78CQ46800350-54A8622A-A72E-4E5B-A8E2-CD433FB1FA1EQ47705368-7177FD6E-6DE6-438A-8B28-6E093F0CECEDQ48104582-34D7D56E-9F14-44EB-ACD7-41698463DC2FQ51041218-8A1F3CCE-7FAB-4D57-99CB-51BD180B0864Q51052873-5E14DF02-C572-4696-A672-F79121C8BC5EQ51738993-39D76427-B9E2-4FD1-827B-E875DAD728BFQ52765818-6D7E8957-4153-4CAE-8485-61B868B937CBQ52926657-4CFB2593-A22A-4233-8CA2-1C1E6A71AAFDQ53174927-348B7E1E-5A1A-42FE-802D-8E7B937CDCAAQ55279019-91BBD098-8F27-4E45-AF9D-B64208A72927Q90473106-A452B052-CF72-4E05-9B94-BE31F510D5A6Q91341621-A8EE1C74-CDE7-4BFC-9513-A5EEC54080D1Q91621874-A9AB2FDF-983B-41F7-A98E-0B51BC0590D3Q93172030-A415B3FB-250D-4C13-AADB-F7F6D287C570
P50
description
Amerikaans onderzoeker
@nl
hulumtues
@sq
investigador estadounidense
@es
investigador estauxunidense
@ast
researcher
@en
հետազոտող
@hy
name
Abhisheak Sharma
@ast
Abhisheak Sharma
@ca
Abhisheak Sharma
@en
Abhisheak Sharma
@es
Abhisheak Sharma
@fr
Abhisheak Sharma
@nl
Abhisheak Sharma
@sl
অভিষেক শর্মা
@bn
type
label
Abhisheak Sharma
@ast
Abhisheak Sharma
@ca
Abhisheak Sharma
@en
Abhisheak Sharma
@es
Abhisheak Sharma
@fr
Abhisheak Sharma
@nl
Abhisheak Sharma
@sl
অভিষেক শর্মা
@bn
prefLabel
Abhisheak Sharma
@ast
Abhisheak Sharma
@ca
Abhisheak Sharma
@en
Abhisheak Sharma
@es
Abhisheak Sharma
@fr
Abhisheak Sharma
@nl
Abhisheak Sharma
@sl
অভিষেক শর্মা
@bn
P108
P1053
V-8401-2017
P106
P1153
55605770235
56294013600
P1960
F6O-KW4AAAAJ
P21
P31
P3829
P496
0000-0003-0553-4039
P569
2000-01-01T00:00:00Z